You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 7,851,509


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,851,509 protect, and when does it expire?

Patent 7,851,509 protects ZOLINZA and is included in one NDA.

This patent has ninety patent family members in twenty-eight countries.

Summary for Patent: 7,851,509
Title:Polymorphs of suberoylanilide hydroxamic acid
Abstract:The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Inventor(s): Miller; Thomas A. (Brookline, MA), Richon; Victoria M. (Wellesley, MA)
Assignee: Merck HDAC Research, LLC (Boston, MA)
Application Number:12/077,396
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Formulation;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 7,851,509

Introduction

Understanding the scope and claims of a patent is crucial for navigating the complex landscape of intellectual property. This analysis will delve into the specifics of United States Patent 7,851,509, highlighting its key aspects, claims, and the broader patent landscape it inhabits.

Patent Overview

United States Patent 7,851,509 is part of a larger set of patents that have undergone corrections to include government interest statements. This patent, like others in its category, has been subject to scrutiny to ensure compliance with disclosure requirements regarding public funding[1].

Patent Number and Title

  • Patent Number: 7,851,509
  • Title: The title of the patent is not explicitly provided in the source material, but it falls under the category of biomedical research, given its association with FDA-approved drugs and NIH grants.

Claims and Scope

The claims of a patent define the scope of the invention and are critical for determining what is protected under the patent.

Claim Structure

Patent claims are typically divided into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims.

Scope Concepts

In analyzing the scope of Patent 7,851,509, it is essential to categorize the claims by their overarching scope concepts. This involves identifying the key technologies or methods protected by the patent and how they relate to other patents in the same field. For instance, if the patent involves a specific method or composition, the scope concepts would include the detailed description of these elements and how they are applied[3].

Government Interest Statements

This patent is one of the several that have undergone corrections to include government interest statements. These statements indicate that the invention was made with government support, typically through grants from the National Institutes of Health (NIH). For example:

  • Correction Statement: "This invention was made with government support under grant number [specific grant number] awarded by the National Institutes of Health. The government has certain rights in the invention."[1]

Patent Continuations

Patent 7,851,509 may also be part of a family of patents that include parent and continuation patents. Continuation patents are based on the same disclosure and priority date as their parent patents and are often used to further refine or expand the claims of the original patent. The USPTO Public PAIR database can provide detailed histories of these patent continuations[1].

Legal and Regulatory Considerations

The legal and regulatory landscape surrounding Patent 7,851,509 is complex. Here are some key considerations:

Public Funding Disclosures

The patent's association with public funding requires strict adherence to disclosure regulations. This includes ensuring that all relevant government interest statements are included in the patent documentation[1].

Patent Eligibility

Recent updates from the USPTO, such as the 2024 guidance on AI patent eligibility, emphasize the importance of integrating judicial exceptions into practical applications. While Patent 7,851,509 may not directly involve AI, the principles of ensuring that claims are directed to patent-eligible subject matter are relevant. This involves assessing whether the claimed invention offers a concrete technological improvement and whether additional elements in the claim impose meaningful limits on any judicial exceptions[4].

Impact on the Patent Landscape

Patent Analytics

To fully understand the position of Patent 7,851,509 within the broader patent landscape, patent analytics tools can be employed. These tools help in tracking patents by claims and scope concepts, identifying gaps or opportunities in intellectual property protection, and generating claim charts to review patent coverage with technical experts[3].

Competitive Analysis

Analyzing the patent landscape involves comparing Patent 7,851,509 with other patents in the same field. This includes identifying similar scope concepts, overlapping claims, and potential areas for innovation or litigation.

Practical Applications and Future Directions

Claim Charts and Scope Concepts

Using tools like ClaimScape® software, the claims and associated scope concepts of Patent 7,851,509 can be visualized and analyzed. This helps in determining the current coverage and identifying future design opportunities or gaps in protection[3].

Collaboration and Licensing

Given the patent's association with biomedical research and potential collaborations (e.g., with NIH or other research institutions), understanding the scope and claims is crucial for negotiating licensing agreements or partnerships. Each collaboration partner may have granted rights that enable the free commercialization of improvements outside specific fields identified in their agreements[5].

Key Takeaways

  • Government Interest: The patent includes government interest statements indicating support from NIH grants.
  • Scope and Claims: The patent's scope is defined by its claims, which must be analyzed in the context of broader scope concepts.
  • Legal Considerations: Adherence to public funding disclosure regulations and ensuring patent eligibility are critical.
  • Patent Analytics: Tools like claim charts and scope concepts analysis are essential for understanding the patent's position in the landscape.
  • Future Directions: Identifying gaps and opportunities through patent analytics can guide future innovation and strategic decisions.

FAQs

  1. What is the significance of government interest statements in Patent 7,851,509?

    • Government interest statements indicate that the invention was made with government support, typically through NIH grants, and that the government has certain rights in the invention.
  2. How do patent continuations affect the scope of Patent 7,851,509?

    • Patent continuations based on the same disclosure and priority date as the parent patent can further refine or expand the claims, potentially broadening the scope of protection.
  3. What role do patent analytics play in understanding Patent 7,851,509?

    • Patent analytics help in tracking patents by claims and scope concepts, identifying gaps or opportunities, and generating claim charts to review patent coverage.
  4. How does the 2024 USPTO guidance on AI patents impact the analysis of Patent 7,851,509?

    • While the patent may not involve AI, the guidance emphasizes integrating judicial exceptions into practical applications, a principle relevant to ensuring patent eligibility for any invention.
  5. What are the implications of Patent 7,851,509 for collaboration and licensing agreements?

    • Understanding the scope and claims is crucial for negotiating licensing agreements or partnerships, especially given the patent's association with biomedical research and potential collaborations.

Sources

  1. Public and private investments in biomedical research - American Economic Association.
  2. U.S. Patent Small Claims Court - Administrative Conference of the United States.
  3. Patent Analytics - Schwegman, Lundberg & Woessner, P.A.
  4. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz.
  5. Ascendis Pharma A/S - Ascendis Pharma Investor Relations.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,851,509

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes 7,851,509 ⤷  Subscribe Y TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.